A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

Prior treatment

• Previous systemic anti-tumor therapy including immune checkpoint inhibitors for NSCLC;
• Previous thoracic radiotherapy;
• Subjects who participated in other clinical trials within 4 weeks or 5 drug half-lives(whichever is shorter) before the first dose;
• Systemic immunostimulant therapy before the first dose;
• Systemic immunosuppressive therapy before the first dose or were expected to require systemic immunosuppressive drugs during the study treatment;
• Clinically significant bleeding symptoms or significant bleeding tendency within 1 month before the first dose;
• Arteriovenous thrombotic events within 3 months before the first dose;
• Serious infection within 4 weeks before the first dose;
• History of attenuated live vaccination 28 days before the first dose or expected to receive attenuated live vaccination during the study;
• Major surgeries other than diagnosis or biopsy within 28 days prior to the first dose;
• Previous or planned allogeneic bone marrow transplantation or solid organ transplantation;

Other illness

• Subjects with autoimmune diseases;
• Other malignant tumors other than non-small cell lung cancer within 5 years before screening;
• Other moderate to severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity and seriously affect respiratory function;
• Severe cardiovascular and cerebrovascular diseases;
• Positive HIV test;
• Active hepatitis B or C;
• Evidence of active tuberculosis infection within 1 year before the first dose;
• History of severe allergic reactions to other monoclonal antibodies/fusion proteins;
• Allergic to any component of the randomized treatment regimen;
• Subjects who have a known history of psychotropic drug abuse, alcoholism, or drug abuse;
• Presence of other conditions that, in the opinion of the investigator, would make participation in this clinical trial inappropriate.

Lab values

• Subjects with driver gene mutations(EGFR mutation, ALK fusion, etc.);

Other

• Histologically or cytologically confirmed mixed SCLC and NSCLC;
• Known or suspected interstitial pneumonia;
• Female subjects who are pregnant, lactating, or planning to get pregnant during the study period;

• 1.18 to 75 years old, both male and female;
• 2.ECOG score: 0-1;
• 3.Histopathologically or cytologically confirmed, stage III (AJCC 8th) non-small cell lung cancer;
• 4.Multidisciplinary team (MDT) discussion confirmed unresectable disease but can be treated by curative radiotherapy;
• 5.Measurable lesions available;
• 6.Major organ function is basically normal;
• 7.Estimated survival time is at least 6 months;
• 8.Non-surgically sterile female subjects of childbearing age must have a negative serum HCG test before inclusion.